Nuevas Tecnologias En Diabetes Y En Endocrinologia S.L. Profesional

Sevilla 30 trials 10 recruiting

30 Registered trials

10 Currently recruiting

Organisation

Nuevas Tecnologias En Diabetes Y En Endocrinologia S.L. Profesional

Location

Sevilla, Spain

Identifier

ORG-100043773

Address

Calle Alejo Fernandez 9, 41003, Spain

Departments

Aliaga Verdugo
Endocrinología
Endocrinology
Endocrinology and metabolism
Endocrinology and Nutrition
Endogrinology and Nutrition
Endrocrinology
N/A
NA
Nephrology
No deparment
Nuevas Tecnologias En Diabetes Y En Endocrinologia S.L. Profesional
Servicio Endocrinologia

Clinical trials at this site (30)

Search interface

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending

2025-523510-87-00 Obesity 5
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD) Pending

2025-525068-13-00 Chronic Kidney Disease 4
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting

2025-523106-32-00 Obesity or Overweight and Type 2 Diabetes 5 2026-05-25
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin ( ENLIGHTEN-6 ) Recruiting

2025-523659-73-00 Obesity 5 2026-05-11
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting

2025-523974-18-00 Obesity 5 2026-04-30
AMAZE 5: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose… Recruiting

2024-520444-42-00 Overweight or obesity, and knee osteoarthritis 5 2026-04-15
AMAZE 6: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose… Recruiting

2024-520445-23-00 Overweight or obesity, and knee osteoarthritis 5 2026-04-15
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee ( ATTAIN-OA PAIN ) Recruiting

2025-522631-34-00 Osteoarthritis 5 2026-01-14
Phase 3 Study of Dotinurad vs Allopurinol in Participants With Gout Recruiting

2024-520206-19-00 Hyperuricemia associated with gout. 5 2025-12-02
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended

2024-520322-11-00 Type 2 Diabetes Mellitus (T2D) 4 2025-09-29
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening);… Ended

2024-519000-27-00 Hypertension 5 2025-07-17
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Chronic Weight Management 5 2025-05-30
A research study comparing how well different doses of the medicine NNC0519-0130 can reduce kidney damage in people living with chronic kidn… Ended

2024-510846-15-00 Chronic Kidney Disease, with or without Type 2 diabetes 4 2025-04-14
REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m… Ended

2023-509600-15-00 Type 2 Diabetes 5 2024-10-18
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes M… Ended

2024-512562-34-00 Type 2 Diabetes Mellitus 4 2025-02-24